November 10, 2015

Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease

These are results as presented at the 2015 American Society of Nephrology Kidney Week.

The effect of empagliflozin vs placebo on cardiovascular events and death was recently reported in the NEJM in Sep 2015, and shown to significantly reduce both the composite cardiovascular primary endpoint and death.

During Kidney Week, the renal outcome of new onset or worsening of nephropathy (defined as a composite of doubling of creatinine, new macroalbuminuria, initiation of RRT or death due to renal disease) was significantly reduced with a hazard ratio of 0.61, P <.0001. The composite endpoint of doubling of serum creatinine, initiation of RRT and death was significantly reduced with a HR of 0.54, p = 0.0002. Full publication of these findings is eagerly awaited.

Related Articles:

Chronic Kidney Disease, Diabetes, General Nephrology

Comments are closed.